Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2025
The effect of T cell-related vaccines on inflammatory bowel disease: A systematic review and meta-analysis.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ding Ning, Dou Dan, Zhao Lu, Zhang Shengsheng, Zhao Luqing
Аннотация
BACKGROUND: The interaction between T cell-related vaccines and the dysregulated immune environment in inflammatory bowel disease (IBD) patients remains unclear.
AIM: To systematically evaluate the immune response of IBD patients following vaccination with T-cell-related vaccines and analyze the impact of immunosuppressive therapy on vaccine response.
METHODS: Multiple databases and preprint platforms were searched, and study quality was assessed using the Newcastle-Ottawa Scale. Data amenable to synthesis were analyzed via Meta-analysis, while non-combinable data were presented as a narrative review.
RESULTS: IBD patients showed no significant difference in spike-specific CD4⁺/CD8⁺ T cell frequencies compared to healthy controls.RBD-IgG titers and sVNT inhibition rates were significantly reduced in IBD patients. Both anti-TNF agents and JAK inhibitors profoundly weakened humoral immunity, whereas gut-selective drugs have minimal impact on antibody responses. Notably, long-term immunosuppression is correlated with broad T-cell functional impairment, though prior infection partially compensated for primary response defects.
CONCLUSION: Overall, T-cell responses remain relatively stable after T-cell-related vaccination in IBD patients, while humoral immunity is significantly impaired. Clinicians should monitor humoral immune indices in patients on immunosuppressive therapy.
AIM: To systematically evaluate the immune response of IBD patients following vaccination with T-cell-related vaccines and analyze the impact of immunosuppressive therapy on vaccine response.
METHODS: Multiple databases and preprint platforms were searched, and study quality was assessed using the Newcastle-Ottawa Scale. Data amenable to synthesis were analyzed via Meta-analysis, while non-combinable data were presented as a narrative review.
RESULTS: IBD patients showed no significant difference in spike-specific CD4⁺/CD8⁺ T cell frequencies compared to healthy controls.RBD-IgG titers and sVNT inhibition rates were significantly reduced in IBD patients. Both anti-TNF agents and JAK inhibitors profoundly weakened humoral immunity, whereas gut-selective drugs have minimal impact on antibody responses. Notably, long-term immunosuppression is correlated with broad T-cell functional impairment, though prior infection partially compensated for primary response defects.
CONCLUSION: Overall, T-cell responses remain relatively stable after T-cell-related vaccination in IBD patients, while humoral immunity is significantly impaired. Clinicians should monitor humoral immune indices in patients on immunosuppressive therapy.